Aktivax wins $15 million contract with BARDA

Technical team to expand to develop auto-injector technology

[BOULDER, COLO]  Aktivax, a Boulder County specialty pharmaceutical company, is expanding its team by more than 20 engineers and other technical staff after being awarded a Department of Health and Human Services (DHHS) Biomedical Advanced Research and Development Agency (BARDA) contract to continue developing its auto-injector platform ARAI. Under an 18-month, $15 million contract with BARDA, Aktivax will advance the development of its ARAI platform technology, combining the ARAI auto-injector with the drug 2-PAM to create ARAI-2PAM. The contract can be extended up to a total of $55 million over four years and could support putting other medications into the ARAI platform. The ARAI auto-injector platform was developed with the support of the US Department of Defense Joint Program Executive Office for Chemical and Biological Defense (JPEO-CBD)/Medical Countermeasure Systems (MCS) office at Fort Detrick, MD, and the Chemical and Biological Defense (CBD) Small Business Innovation Research (SBIR) program managed by the Joint Science and Technology Office for Chemical and Biological Defense (JSTO-CBD) at Fort Belvoir, VA. JSTO-CBD is part of the Defense Threat Reduction Agency (DTRA). The SBIR Phase I and Phase II funding contributed significantly to Aktivax reaching a product maturity level and technical validation that allowed BARDA to participate. 

 “We are very excited to continue supporting the Government mission to protect US troops and the civilian population from unconventional weapon threats,” said Amir Genosar, the company’s founder and CEO. “We appreciate BARDA’s trust in our capability to improve preparedness.” Aktivax will be relocating its offices from the current Boulder location to Broomfield to allow the expansion of the team and be more accessible for talent from the Denver metro area. “We are looking to bring in a diversity of local talent in engineering, quality, regulatory, purchasing, and Chemistry Manufacturing & Controls (CMC) to take part in this exciting journey,” said Jeff Steward, Aktivax’s VP of Engineering. “We believe that our rewarding, fun, and balanced life environment combined with cutting-edge technology and human-centric mission will attract excellent individuals and help us establish an outstanding, diverse team. The company is excited to create job opportunities in Colorado and give back to our community.”

In the near future, Aktivax will leverage the progress made under the BARDA contract to pursue consumer market emergency products such as severe allergy treatment, hypoglycemia, and opioid overdose. “Not surprisingly, the Government's need for robust, user-friendly auto-injectors with improved drug stability is similar to the needs of consumer markets” said Amir. “Our mission is simply to provide people at risk, and their communities, peace-of-mind that a lifesaving treatment will be delivered when and where needed.”

For more information about Aktivax please contact info@aktivax.com